Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): From mechanistic insights to therapeutic applications

Gian Luca Erre, Marco Sebastiani, Andreina Manfredi, Elisabetta Gerratana, Fabiola Atzeni, Giuseppe Passiu, Arduino A. Mangoni

    Research output: Contribution to journalReview articlepeer-review

    1 Citation (Scopus)

    Abstract

    Fibrosing interstitial lung disease (ILD) is one of the most important causes of morbidity and mortality in patients with connective tissue diseases (CTDs), which include systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, idiopathic inflammatory myositis and systemic lupus erythematosus. The treatment of CTD-ILDs is challenging due to the paucity of proven effective treatments. Recently, two antifibrotic drugs conditionally approved for use in patients with idiopathic pulmonary fibrosis, nintedanib and pirfenidone, have been trialled in CTD-ILDs based on overlapping pathological and clinical features between the two diseases. In this narrative review, we discuss the experimental evidence and clinical trials investigating the efficacy and safety of antifibrotic drugs in patients with CTD-ILDs and the potential mechanisms of action involved. Results from clinical trials suggest that nintedanib use retards lung function decline in progressive fibrotic CTD-ILDs. By contrast, the evidence for the efficacy of pirfenidone in these groups is not equally compelling. Further, well-designed randomized clinical trials are needed to evaluate the efficacy and safety of individual antifibrotic drugs in specific CTD-ILD subgroups.

    Original languageEnglish
    Article number86
    Number of pages13
    JournalDrugs in Context
    Volume10
    DOIs
    Publication statusPublished - 15 Jan 2021

    Keywords

    • Connective tissue diseases
    • Idiopathic inflammatory myopathies
    • Interstitial lung disease
    • Nintedanib
    • Pirfenidone
    • Rheumatoid arthritis
    • Sjögren's syndrome
    • Systemic sclerosis

    Fingerprint Dive into the research topics of 'Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): From mechanistic insights to therapeutic applications'. Together they form a unique fingerprint.

    Cite this